

60. Kaye SB, Lewis CR, Paul J, et al. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. *Lancet* 1992; 340: 329-33
61. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. *J Clin Oncol* 1989; 7: 1748-56
62. Calvert AH, Newell DR, Gore ME. Future directions with carboplatin: can therapeutic monitoring, high-dose administration, and hematologic support with growth factors expand the spectrum compared to cisplatin? *Semin Oncol* 1992; 19: 155-63
63. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. *J Clin Oncol* 1992; 10: 520-28
64. Hills CA, Kelland LR, Abel G, et al. Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes. *Br J Cancer* 1989; 59: 527-34
65. Reed E, Janik J, Bookman MA, et al. High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer. *J Clin Oncol* 1993; 11: 2118-26
66. Timmer-Bosscha H, Mulder NH, de Vries EGE. Modulation of cisdiamminedichloroplatinum (II) resistance: a review. *Br J Cancer* 1992; 66: 227-38
67. Knox RJ, Friedlos F, Lydall DA, et al. Mechanism of cytotoxicity of anticancer platinum drugs: evidence that *cis*-diamminedichloro platinum(II) and *cis*-diammine(1,1-cyclobutanedicarboxylato) platinum (II) differ only in the kinetics of their interaction with DNA. *Cancer Res* 1986; 46: 1972-9
68. Kelland LR, Barnard CFJ, Mellish K, et al. A novel trans platinum coordination complex possessing in vitro and in vivo antitumour activity. *Cancer Res* [submitted]

Correspondence and reprints: Dr L.R. Kelland, CRC Centre for Cancer Therapeutics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, England.

Errata

Vol. 4, No. 6, p. 515: The dark purple circle in figure 2 should contain the letters 'AChE' (acetylcholinesterase), while the dark purple oval should contain the letters 'CAT' (choline acetyltransferase).

Vol. 4, No. 6, p. 518: The 2 purple circles in figure 3 should contain the letters 'MAO' (monoamine oxidase).

[Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. *Drugs & Aging* 1994; 4 (6): 510-540]